On December 11, 2018, FDA issued final guidance on interpreting the
"Deemed to be a License" provision of BPCIA. The guidance
provides FDA's interpretation of the provision and its
recommendations to sponsors of proposed protein products.
According to the guidance, an approved NDA for a biological
product shall be deemed to be a BLA for the product as of the
transition date, March 23, 2020. Examples of such products are
provided in the guidance's appendix. As of the transition date,
the approved NDA will no longer exist, FDA will remove the product
from the Orange Book, and FDA will no longer consider any listed
patents as relevant for the timing of approving a 505(b)(2)
application or ANDA for the product.